Andrew Huberman on proposed 40% NIH budget cuts: 'You can't overstate the importance of NIH funding basic and applied research'

Summary

Andrew Huberman's appearance centers on a single question with large consequences: what does a 40% cut to the NIH research budget actually mean, and is the public backlash against science funding justified?

The budget threat

Congress is expected to vote in September on a proposal to cut the NIH's overall research budget by 40%. Separately, the Trump administration has already moved to cap indirect cost reimbursements to universities at 15% across the board — down from rates that typically run between 30% and 75% of a grant's direct value. Huberman argues the indirect cost cap, while superficially appealing, would disproportionately hurt public universities with small endowments, which have no reserves to absorb the shortfall. A cap closer to 30% strikes him as more defensible. The 40% headline cut is the bigger concern — it touches the entire research budget, not just administrative overhead.

Why the backlash has legs

Huberman doesn't dismiss the public anger. He identifies two grievances that are driving even politically mixed audiences to oppose NIH funding. First, many people — including prominent Silicon Valley investors and founders — want formal acknowledgment that pandemic-era policies, particularly lockdowns, disproportionately harmed the non-laptop class: janitors, teachers, hourly workers. Second, there's accumulated frustration over what Huberman describes as the scientific community's reluctance to publicly acknowledge its own errors, pointing to the Alzheimer's research fraud scandal as a case in point. The replication crisis feeds the same distrust. His read is that the public isn't anti-science so much as angry about institutional opacity — and that anger is now threatening funding that has nothing to do with those failures.

Huberman also separates the Harvard and Columbia funding freezes from the broader NIH debate. Those freezes stem from civil rights law disputes with the current administration, not from NIH policy — though the two issues get conflated in public discourse because they share the same funding pipeline.

What NIH actually funds — and a dirty secret

NIH funds two distinct categories: basic research (cell biology, neuroscience, immunology — non-patentable, non-commercial) and applied research, including clinical trials. Huberman argues the majority of both in the United States runs through NIH, making it the dominant funding body globally. He credits NIH-backed work for most of the Nobel prizes in physiology, medicine, and chemistry.

But he also surfaces an uncomfortable structural reality: much NIH-funded research is, by the time it's funded, already effectively completed. Grants are awarded based on preliminary data showing the work is likely to succeed, which systematically favors incremental science over high-risk hypotheses. Truly bold research tends to get funded by foundations or bodies like the Howard Hughes Medical Institute, which Huberman describes as the equivalent of three NIH grants per year in funding flexibility. His inference is that NIH, as currently structured, may be better at validating science than generating breakthroughs — and that reform, not just cuts, is the more honest conversation.

Where the funding should go

On priorities, Huberman argues the framework should be epidemiological: rank the leading causes of death and disability — dementia, major depression, stroke, Parkinson's, glaucoma — and allocate accordingly. He's cautiously supportive of the Make America Healthy Again emphasis on chronic disease and lifestyle factors, but warns it shouldn't crowd out mechanistic biology. His example: GLP-1 agonists emerged from a researcher studying the Gila monster's metabolism, not from a targeted obesity program. Semaglutide works by increasing a naturally occurring peptide roughly a thousandfold, suppressing appetite at both the gut and brain level. That discovery required decades of basic science with no obvious commercial application at the outset.

The peptide gap

A thread that runs through the conversation is the absence of clinical trial data on naturally occurring peptides that can't be patented. BPC-157, for instance, has solid animal data on healing but no human trials, because no drug company has an incentive to fund them. Huberman mentions pinealon — a peptide he takes personally at roughly $15 a month — as another example. He says it gives him 2.5 hours of REM sleep in a six-hour sleep window, but acknowledges there are no clinical trials to confirm safety or efficacy. He contrasts this with the new class of orexin-receptor antagonists (the DORAs), which work by suppressing wakefulness rather than sedating — a cleaner mechanism — but cost around $325 a month because they're patented. The market structure means well-studied expensive drugs get prescribed while cheaper, unpatentable compounds circulate in the biohacking gray market with no rigorous human data.

Stem cells and the limits of deregulation

Huberman draws a hard line on stem cells. A Florida clinic previously injected stem cells into the eyes of patients with macular degeneration; those patients went permanently blind. A well-known physician in the wellness community was nearly permanently paralyzed from a stem cell injection into a spinal disc. Huberman's position is that stem cells are not ready for clinical use outside controlled trials, and that the current regulatory caution in the US exists for documented reasons — not bureaucratic inertia.

Podcaster responsibility

Huberman argues that health podcasters with large audiences carry an underappreciated obligation to separate explanation from endorsement. He takes heat from both sides — from the natural health community when he covers ADHD stimulants, and from pharmaceutical advocates when he covers behavioral interventions. He says the clinical data on microdosing psilocybin for depression is essentially negative, while the data on high-dose psilocybin (2–4 grams) administered in structured clinical settings, from trials at UCSF and elsewhere, shows meaningful results for treatment-resistant depression and PTSD. MDMA-assisted therapy for PTSD went to the FDA last year and was not approved. His point is that the distinction between macro and micro dosing matters, and that broadly endorsing either without that nuance is the kind of irresponsibility that erodes public trust in both science and media.

Takeaway

The 40% NIH budget cut is the operative number. Huberman's argument is that the public anger driving political support for those cuts is real and not entirely unreasonable — pandemic messaging failures and scientific fraud were real — but that cutting the research budget is the wrong remedy. The more defensible reform is structural: prioritize high-risk funding, fix indirect cost transparency, and be honest about the NIH's current bias toward incremental science. Dismantling the system that produced GLP-1s, CRISPR, and most of the country's clinical trial infrastructure is a different category of decision from holding universities accountable.